Ate-Bev Early Response Prediction Model in Advanced HCC

Last updated: May 12, 2025
Sponsor: Seoul National University Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Carcinoma

Digestive System Neoplasms

Abdominal Cancer

Treatment

Early response evaluation

Clinical Study ID

NCT05763277
2206-066-1332
  • Ages 18-80
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The prognosis of hepatocellular carcinoma is poor compared to other carcinomas. Many drugs have recently been developed, and recently, atezolizumab-bevacizumab treatment was superior to sorafenib, the conventional treatment for advanced hepatocellular carcinoma. However, there is no information on the evaluation on the evaluation of treatment response for atezolizumab-bevacizumab combination therapy compared to atezolizumab alone or bevacizumab alone. Therefore, this study aimed to create a predictive model that can detect treatment response at an early stage.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients who were diagnosed with advanced hepatocellular carcinoma and who werescheduled to receive atezolizumab-bevacizumab as the first-line therapy

  • Patients willing to participate in this study

Exclusion

Exclusion Criteria:

  • Individuals with a history of severe contrast allergy

  • Individuals with severe comorbidities (according to the American Society of ClinicalOncology-Friends of Cancer Research Organ Dysfunction.)

Study Design

Total Participants: 170
Treatment Group(s): 1
Primary Treatment: Early response evaluation
Phase:
Study Start date:
July 22, 2022
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • Seoul National University Hospital

    Seoul,
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.